6 completed, 2 not yet recruiting, 2 recruiting, 1 terminated. 11 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 6, Not yet recruiting 2, Recruiting 2, Terminated 1 |
| Phase 2 | 3 | Completed 2, Not yet recruiting 1 |
Follow IgA Nephropathy: new trials by email Literature Review of IgA Nephropathy trials Research Report on IgA Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants Budesonide delayed release tablet - IgA Nephropathy | Phase 1 | Not yet recruiting | Triastek, lnc. | 18 | 2026-10-01 | 2026-10-27 |
| Study of BHV-1400 in IgA Nephropathy BHV-1400 - IgA Nephropathy | Phase 1 | Recruiting | Biohaven Therapeutics Ltd. | 20 | 2025-07-30 | 2026-06-23 |
| A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects HRS-5965 Capsules - IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 16 | 2025-06-30 | 2025-08-20 |
| A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases SCTC21C - IgA Nephropathy | Phase 1 / Phase 2 | Not yet recruiting | Sinocelltech Ltd. | 99 | 2025-01-01 | 2025-01-14 |
| Study of ARO-CFB in Adult Healthy Volunteers ARO-CFB, Placebo - IgA Nephropathy | Phase 1 | Completed | Arrowhead Pharmaceuticals | 49 | 2024-04-05 | 2026-05-20 |
| A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects HS-10390 tablet, Placebo tablet - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 1 | Recruiting | Hansoh BioMedical R&D Company | 84 | 2023-05-23 | 2024-10-09 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject SHR-2010 injection, SHR-2010 injection placebo - IgA Nephropathy | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 61 | 2022-06-30 | 2023-03-23 |
| Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease ARO-C3, Placebo - C3 Glomerulopathy, IgA Nephropathy | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 62 | 2022-02-01 | 2026-05-22 |
| Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses - IgA Nephropathy | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 103 | 2019-04-08 | 2026-06-16 |
| First in Human Study to Assess Safety of VIS649 in Healthy Subjects VIS649, Placebo - Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 51 | 2018-10-09 | 2026-05-01 |
| Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy OPL-CCL2-LPM - IGA Nephropathy, Proteinuria | Phase 1 | Terminated | Osprey Pharmaceuticals USA, Inc. | 30 | 2009-03-01 | 2010-06-02 |
Glomerulonephritis, IGA (11) · Proteinuria (2) · Glomerulonephritis (1) · Glomerulosclerosis, Focal Segmental (1) · Hemoglobinuria, Paroxysmal (1) · Kidney Diseases (1) · Nephritis (1) · Renal Insufficiency, Chronic (1) · Urologic Diseases (1)
Autoimmune Diseases (11) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Immune System Diseases (11) · Male Urogenital Diseases (11) · Urogenital Diseases (11) · Glomerulonephritis (10) · Kidney Diseases (10) · Nephritis (10) · Urologic Diseases (10) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Urination Disorders (2) · Urological Manifestations (2) · Anemia (1)
Arrowhead Pharmaceuticals (2) · Biohaven Therapeutics Ltd. (1) · Chengdu Suncadia Medicine Co., Ltd. (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Hansoh BioMedical R&D Company (1) · Novartis Pharmaceuticals (1) · Osprey Pharmaceuticals USA, Inc. (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Sinocelltech Ltd. (1) · Triastek, lnc. (1)
China (5) · United Kingdom (3) · United States (3) · New Zealand (2) · South Korea (2) · Australia (1) · Canada (1) · Georgia (1) · Germany (1) · Thailand (1)
Bryan Curtis, M.D. (1) · Esther Yoon, MD (1) · Hong Zhang (1) · Michelle Hladunewich, M.D. (1) · Vincent Pichette, M.D., Ph.D. (1)
PMID 38299639, PMID 35570983, PMID 40297949, PMID 40482854, PMID 42275148
2018 (1), 2023 (1)